x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

35:27

Episode 147: David Fajgenbaum on Covid-19 drugs, the...

The Readout Loud ·

2021/02/11

When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we check in with our colleague Helen Branswell for her view on the current state of the Covid-19 pandemic and the ongoing vaccine rollout. Then, we're joined by David Fajgenbaum, a physician and scientist at the University of Pennsylvania, to talk about his work

en

34:16

Episode 146: Paul Offit on vaccine data, 23andMe is...

The Readout Loud ·

2021/02/04

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck CEO Ken Frazier's retirement after three decades at the drug maker, and how the future of Biogen’s Alzheimer’s disease drug got a little more complicated. Then, Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, joins us to weigh in on the bounty of recent

en

34:16

Episode 145: Kevin Davies on the CRISPR boom, & Megan...

The Readout Loud ·

2021/01/28

First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the strange boom in genome editing stocks and the future of the revolutionary technology. Finally, we talk to Megan Ranney, an emergency room physician and Brown University professor, about the challenges of Covid-19 science communication in a post-Trump world.

en

39:40

Episode 144: Remembering STAT's Sharon Begley

The Readout Loud ·

2021/01/22

We're spending this entire episode remembering Sharon Begley, our revered and beloved colleague who died last week from complications of lung cancer. First, STAT's Eric Boodman joins us to discuss Sharon's path-breaking career and what he learned from reporting out her obituary. Then, a trio of STAT editors call in to talk about what it was like to work with Sharon, and we hear from number of her colleagues about what made her a singular writer, mentor, officemate, and friend.

en

29:59

Episode 143: #JPM21: Déjà vu in Alzheimer's research,...

The Readout Loud ·

2021/01/14

We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp

en

29:14

Episode 142: Bob Nelsen on the pandemic's next phase,...

The Readout Loud ·

2021/01/07

On this year's first episode, STAT Washington correspondent Lev Facher joins us to break down the implications of a Democrat-controlled Senate. Then, our colleague Erin Brodwin calls in to talk about CES, the massive tech conference taking place next week. Finally, we chat with Bob Nelsen, a biotech venture capitalist and one of the few people who saw the coming pandemic with clarity months before everyone else, about what's ahead in 2021.

en

34:55

Episode 141: Moderna's vaccine milestone, Warp...

The Readout Loud ·

2020/12/18

It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.

en

33:50

Episode 140: Pfizer's Covid-19 vaccine — the debate,...

The Readout Loud ·

2020/12/11

Are Covid-19 vaccines safe for teens? Is the U.S. taking too long to authorize one? And how do you prepare for an FDA grilling?

en

28:38

Episode 139: Angela Rasmussen on AstraZeneca's...

The Readout Loud ·

2020/12/03

Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And how do you make blind mice see again?

en

23:07

Episode 138: The latest Covid-19 vaccine, Biden's...

The Readout Loud ·

2020/11/19

How do we measure whether Covid-19 vaccines work? What does Joe Biden think of the drug industry? And does Anthony Fauci think about retirement?

en

29:23

Episode 137: Natalie Dean on Pfizer's Covid-19...

The Readout Loud ·

2020/11/12

How well does Pfizer's Covid-19 vaccine work? What's the difference between efficacy and effectiveness? And should the FDA approve Biogen's Alzheimer's drug?

en

26:42

Bracing for a pandemic winter, Biogen's fortune at...

The Readout Loud ·

2020/11/05

How bad will this winter be? Is everything coming up Biogen? And who's going to be president on Jan. 20? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. First, STAT's Helen Branswell joins us to discuss what the winter has in store for the ongoing Covid-19 pandemic. Then, we discuss the latest surprising twist in Biogen’s quest to win FDA approval for a polarizing treatment for Alzheimer’s disease. Finally, STAT reporter Casey Ross joins to talk

en

29:52

Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on...

The Readout Loud ·

2020/10/29

When are we getting Covid-19 vaccine data? Will concerts ever be safe again? And what's a "Bionomy"?

en

24:59

Episode 134: Erik Gordon on SPACs, plus Covid-19...

The Readout Loud ·

2020/10/22

Who's voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?

en

28:06

Episode 133: A week of pauses, pharma’s statehouse...

The Readout Loud ·

2020/10/15

Is your local lawmaker flush with pharma cash? How does racism in medicine loom over Covid-19 studies? And who decides when a clinical trial goes on pause?

en

23:07

Episode 132: How Trump's case of Covid-19 affects...

The Readout Loud ·

2020/10/08

Why is the president making drug ads? Are antibodies the new vaccines? And is it ethical for doctors to talk about President Trump's health?

en

25:06

Episode 131: Saad Omer on Covid-19 vaccine trials, &...

The Readout Loud ·

2020/10/01

Can an itchy arm ruin a clinical trial? Does intermittent fasting work? And is pharma more trustworthy than the CDC?

en

25:46

Episode 130: A road map for Covid-19, the gold rush...

The Readout Loud ·

2020/09/24

Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?

en

26:25

Episode 129: Heidi Tworek on pandemic PR, plus the...

The Readout Loud ·

2020/09/17

How should governments talk about Covid-19? Can the Centers for Disease Control and Prevention rebuild public trust? And when is a steak worth $21 billion?

en

25:03

Episode 128: AstraZeneca’s Covid-19 vaccine,...

The Readout Loud ·

2020/09/10

Is AstraZeneca’s Covid-19 vaccine in jeopardy? Why can’t politicians and scientists in Washington get along? Did you miss STAT’s first-ever Health Tech Summit?

en

388 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...